A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

NCT07389733

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Shandong Suncadia Medicine Co., Ltd.
Enrollment	180 participants

Key Eligibility Criteria

Inclusion (6)

- Female, aged 18-75 (inclusive);
- ECOG score 0-1;
- Estimated survival time e 12 weeks;
- Possessing adequate bone marrow and organ function;
- Participants of reproductive/childbearing potential must agree to take adequate and effective contraceptive measures from the time they sign the informed consent form, during the study treatment period, and up to 2 years after the last use of the trial medication;

... and 1 more (see full listing online)

Exclusion (17)

- Within 5 years prior to the first dose of study medication, the occurrence of other malignancies, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, and post-radical surgery thyroid papillary carcinoma;
- Active brain metastasis, carcinomatous meningitis, spinal cord compression, or history of primary central nervous system tumors;
- Severe bone damage caused by tumor bone metastasis as determined by the investigator;
- Adverse events caused by previous anti-tumor treatment have not been resolved;
- Participants with one of multiple factors affecting oral medication;

... and 12 more (see full listing online)

Locations (2 total)

The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China